Related Experiment Video
Updated: Apr 8, 2026

Synthesis of Stimuli-responsive Nanogels using Aqueous One-step Crosslinking and Co-nanopolymerization
Published on: January 24, 2025
The Future of Biologics: Lessons from Hatch-Waxman
Brian J Miller1,2, Janet Woodcock3
1Division of Hospital Medicine, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, MD, USA. brian@brianjmillermd.com.
Abstract:
The article review the challenges and lack of robust biologics market competition and drug pricing impacts, the history of the small molecule generics marketplace and the subsequent early evolution of the biosimilar marketplace. The article then explores the potential of an abbreviated biologics license application pathway to market-akin to the market entry pathway for generics-as a policy lever for improving biologics drug price competition, drug affordability and expanded access.
Related Concept Videos
Drug Products: Biologics, Biosimilars and Interchangeables
Upstream Processing
Bioequivalence studies: Biowaivers
Hybridoma Technology
Hybridoma Selection
Commonly used fusion techniques — electroporation,...
Biopharmaceutical Factors Influencing Drug Product Design: Overview
Microorganisms in Medicine and Therapeutics

